Jaguar Health is a going-concern nano-cap that sold its only approved United States commercial franchise for a one-time cash infusion and is now asking common holders to finance an orphan powder program whose clinical package is still unfinished, against a royalty clock that restarts this autumn and a share count that keeps being reverse-split to remain listed.
The January transaction with Woodward Specialty, the Future Pak affiliate that already owns an HIV commercial stack, is the event that rewired the model rather than a routine out-license. Exclusive United States marketing rights to Mytesi and Canalevia-CA1 moved across the table, Jaguar dissolved its own sales group, and the company became a cost-plus manufacturer while booking a $16 million close payment. A later $3 million fee arrived when management extinguished the contractual right to buy those rights back, which permanently sold the option to recapture the franchise if the rare-disease bet later justified owning the brand again. That is not a partnership that leaves Jaguar with a royalty stream on the approved tablet. It is a sale of the cash-generating identity in exchange for a thinner cost base and a single burst of non-dilutive capital.
Cash at mid-year did not match the new identity. Unrestricted cash was about $4 million, notes payable still sat near $16 million, and the auditor's going-concern language remained in place even after the license windfall. Two royalty facilities restart minimum monthly draws in October at a combined claim that can exhaust the remaining cash in a handful of months unless a partner or the equity line refills the account. Common holders have already lived through a spring reverse split plus a newly announced autumn consolidation, which is the capital-markets signature of a company that shrinks the share count to stay listed rather than growing the franchise to stay solvent.
The debate resolves on two observables rather than on another quarter of cost-plus bottles. Either the microvillus inclusion disease package is complete enough by year-end to support a filing in the second quarter of next year and the June strategic-alternatives process produces a funder before the royalty restart, or the equity remains a serial-dilution residual on an unfunded orphan story.